Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

March 27, 2025 updated by: Mirza Zeeshan Sikandar, Central Park Medical College

Assessment of Impact of Rosuvastatin Doses on Low Density Lipoprotein Levels, Creatinine Phosphokinase Levels and Aspartate Aminotransferase Levels: A Randomized Controlled Trail

Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

195

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan, 54600
        • Central Park Teaching Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

patients who were already on statins

Exclusion Criteria:

hereditary diseases including familial hypercholesterolemia and kidney diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 1
receiving drug dose of 5mg
Drug: Rosuvastatin
a dose of 5mg were given and were compared for the cpk, ast and ldl levels
Drug: Rosuvastatin
a dose of 10 mg were given and were compared for the cpk, ast and ldl levels
Drug: Rosuvastatin
a dose of 20 mg were given and were compared for the cpk, ast and ldl levels
Active Comparator: Group 2
receiving grug dose of 10 mg
Drug: Rosuvastatin
a dose of 5mg were given and were compared for the cpk, ast and ldl levels
Drug: Rosuvastatin
a dose of 10 mg were given and were compared for the cpk, ast and ldl levels
Drug: Rosuvastatin
a dose of 20 mg were given and were compared for the cpk, ast and ldl levels
Active Comparator: Group 3
receiving dose of 20 mg
Drug: Rosuvastatin
a dose of 5mg were given and were compared for the cpk, ast and ldl levels
Drug: Rosuvastatin
a dose of 10 mg were given and were compared for the cpk, ast and ldl levels
Drug: Rosuvastatin
a dose of 20 mg were given and were compared for the cpk, ast and ldl levels

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
impact of rosuvstatin over LDL, CPK and AST levels
Time Frame: 12 weeks
Pre- and post intervention levels of fasting serum low-density lipoprotein (LDL) in mg/dL were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin.
12 weeks
impact of rosuvstatin over LDL, CPK and AST levels
Time Frame: 12 weeks
Pre- and post-intervention levels of creatine phosphokinase (CPK) in mcg/L were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin in terms of rhabdomyolysis.
12 weeks
impact of rosuvstatin over LDL, CPK and AST levels
Time Frame: 12 weeks
Pre- and post-intervention levels of Aspartate Aminotransferase (AST) in U/L were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin in terms of liver damage.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central Park Medical College

Investigators

  • Principal Investigator: Sikandar, Central Park Medical College
  • Principal Investigator: Sikandar, Central Park Medical College & Teaching Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2023

Primary Completion (Actual)

June 30, 2024

Study Completion (Actual)

August 31, 2024

Study Registration Dates

First Submitted

March 22, 2025

First Submitted That Met QC Criteria

March 27, 2025

First Posted (Actual)

April 4, 2025

Study Record Updates

Last Update Posted (Actual)

April 4, 2025

Last Update Submitted That Met QC Criteria

March 27, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PHRF/RCT/238

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rosuvastatin

Clinical Trials on Rosuvastatin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe